Search Results
Your search for ,loW matches 7077 pages
Showing 5101 - 5150Selected Abstracts From 2015 ASH Annual Meeting: Part 3
Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on the topic of anticoagulation and the cancer patient. For other selected abstracts from this conference, see the December 25, 2015, and the...
Geriatric Assessment Is Key to Treatment Decisions for Patients 80 Years and Older With Breast Cancer
A review of major studies and the current literature underscored the role of geriatric assessment in making treatment recommendations for patients aged 80 years and older with early and metastatic breast cancer. The review was reported by Shachar et al in the Journal of Oncology Practice. The...
Expert Point of View: Kathy S. Albain, MD, FACP, FASCO, and Jame Abraham, MD
The general consensus of breast cancer experts of the initial findings of BCIRG-006 triggered a more judicious use of anthracyclines, and this trend continues. Kathy S. Albain, MD, FACP, FASCO, Professor of Medicine at Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, said...
2015 Palliative Care in Oncology Symposium Highlights
The Palliative Care in Oncology Symposium, held October 9–10, 2015, in Boston, Massachusetts, brought together more than 670 members of the cancer care community, including oncologists, radiologists, palliative care specialists, nurses, and patient advocates. Sessions delivered information on...
ASCO’s Incoming President-Elect Charts His Course for 2017
Bruce E. Johnson, MD, FASCO, was elected ASCO President for the 2017–2018 term this past December and will take office as President-Elect during the ASCO Annual Meeting, June 3–7, 2016, in Chicago. As an ASCO member since 1986, Dr. Johnson brings over 30 years of experience with ASCO to the...
PET Scan Use in Follow-up Care for Lung and Esophageal Cancer Shows Wide Variation Between Hospitals, No Impact on Survival
A new study suggests that one approach to watching for a cancer's return is being inappropriately used at many hospitals and isn't helping patients survive longer. The findings are published by Healy et al in the Journal of the National Cancer Institute. The study looked at how often survivors ...
CAR-T Cell Therapy May Have Role in Treating Multiple Myeloma
Among the burgeoning options for treating multiple myeloma could be an approach that is proving to be exciting in leukemia: CAR-T (chimeric antigen receptor T cells) therapy. Preliminary results of the first-in-humans study in myeloma were presented as a late-breaking abstract at the 2015 ASH...
Expert Point of View: Daniel Hamstra, MD
Formal discussant of these trials Daniel Hamstra, MD, of Texas Center for Proton Therapy, Irving, offered his perspective. With increased doses of radiation using additional conventional fractions, tumor control is improved, but the risk of damage to normal tissue is increased. Hypofractionation is ...
Half of Elderly Patients With Colorectal Cancer Receive Expensive Therapy With Little Survival Benefit
A study published by Bradley et al in Medical Care showed that over a recent 10-year period, the rate of metastatic colorectal cancer patients older than age 75 receiving three or more treatments increased from 2% to 53%. During this period, 1-year treatment costs increased 32% to reach an...
Children With Leukemia From High-Poverty Areas More Likely to Suffer Early Relapse
Among children with acute lymphoblastic leukemia (ALL), the most common pediatric cancer, those who live in high-poverty areas are substantially more likely to suffer early relapse than other patients, despite having received the same treatment, according to new research from Dana-Farber/Boston...
Hypofractionation Is Ready for Prime Time in Prostate Cancer, but Will It Be Adopted?
Separate phase III trials presented at the 2016 Genitourinary Cancers Symposium demonstrated that modest hypofractionated radiotherapy is noninferior to conventional radiotherapy for men with intermediate- and low-risk prostate cancer and should be considered a new standard of care.1,2 However, it...
Radiolabeled Somatostatin Analog May Represent A Paradigm Change in the Treatment of Neuroendocrine Tumors
A radiolabeled somatostatin analog compound, 177Lu-DOTA0-Tyr3-Octreotate (Lu-177 dotatate), reduced the risk of disease progression or death by 79% in the international phase III NETTER-1 population of previously treated, advanced neuroendocrine tumors of midgut origin.1 Lu-177 dotatate belongs to...
Neratinib Shows Some Activity in Previously Treated HER2-Positive Breast Cancer Brain Metastases
In the phase II Translational Breast Cancer Research Consortium (TBCRC) 022 study, reported by Freedman et al in the Journal of Clinical Oncology, the erbB1, HER2, erbB4 inhibitor neratinib showed some activity in patients with HER2-positive breast cancer brain metastases. Study Details In the...
New Biomarker Identifies Uveal Melanoma Patients at High Risk for Metastasis
Among uveal melanomas categorized as class 1, those with high levels of PRAME mRNA were more likely to metastasize than those with low levels of PRAME mRNA, suggesting that patients who have class 1 uveal melanoma with high levels of PRAME mRNA should be monitored more closely for metastatic...
Metabolic Phenotyping of Blood Plasma Allows for the Detection of Lung Cancer
Metabolic phenotyping of blood plasma by proton nuclear magnetic resonance (H-NMR) identified unique metabolic biomarkers specific to lung cancer patients and allowed for the accurate identification of a cohort of patients with early and late-stage lung cancer. These findings were published by...
Malignant Brain Tumors Most Common Cause of Cancer Deaths in Adolescents and Young Adults
A new report published by Ostrom et al in the journal Neuro-Oncology sponsored by the American Brain Tumor Association (ABTA) found that malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15 to 39, and the most common cancer occurring...
FDA Approves Everolimus for Neuroendocrine Tumors of Gastrointestinal or Lung Origin
The U.S. Food and Drug Administration today approved everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated nonfunctional neuroendocrine tumors of gastrointestinal or lung origin with unresectable, locally advanced, or metastatic disease. ...
Increased Cancer Mortality Among Recipients of Solid-Organ Transplants
Solid-organ transplant recipients have a higher rate of cancer mortality than that expected in the general population, according to a Canadian study published in JAMA Oncology. Cancer mortality among transplant recipients “was significantly elevated compared with the Ontario population,” with a...
UK Trial Shows No Survival Benefit of Low–Molecular-Weight Heparin in Patients With Lung Cancer
In the UK phase III FRAGMATIC trial reported in the Journal of Clinical Oncology, Macbeth et al found no survival benefit of adding low–molecular-weight heparin to standard treatment in patients with lung cancer. Previous evidence suggested that low–molecular-weight heparin might...
ASCO Endorses Cancer Care Ontario Guideline on Active Surveillance for Management of Localized Prostate Cancer
As reported by Ronald C. Chen, MD, MPH, of the University of North Carolina at Chapel Hill, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed, with qualifications, the 2015 Cancer Care Ontario (CCO) guideline on active surveillance for management of localized prostate cancer....
100% of NCI-Designated Cancer Centers Endorse the Promotion of the HPV Vaccination for Cancer Prevention
All National Cancer Institute (NCI)-designated cancer centers have united to support human papillomavirus (HPV) vaccination (see below). A team of HPV experts drafted a consensus statement that advises widespread use of HPV vaccines to prevent cancer. HPV causes cancer of the cervix, anus, and...
2016 Head and Neck Cancer Symposium: Chemoradiation May Increase Survival for a Subset of Elderly Head and Neck Cancer Patients
The addition of chemotherapy to radiation therapy improves survival rates among a subset of elderly head and neck cancer patients, specifically those aged 71 to 79 with low comorbidity scores and advanced disease stage, according to research presented by Amini et al at the 2016 Multidisciplinary...
2016 Head and Neck Cancer Symposium: Most Recurrences of HPV-Positive Oropharyngeal Cancer Can Be Found Within 6 Months
For patients treated with definitive radiation therapy for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at 3 months and physical exams during the 6 months following treatment, according to research presented by...
Jaclyn Biegel, PhD, Joins Children’s Hospital of Los Angeles as Director of Center for Personalized Medicine
Children’s Hospital Los Angeles (CHLA) has named Jaclyn Biegel, PhD, a leading academic expert on pediatric brain tumors, rhabdoid tumors, and cancer cytogenetics, as the Director of the Center for Personalized Medicine at CHLA. Dr. Biegel, who formerly served as Director of the Cancer Cytogenetics ...
Global Cancer: The Current Reality and the Future Need for Action
The estimated number of cancer cases worldwide in 2008 was 12.7 million, with 7.6 million deaths. By 2030, it is estimated that there will be 22 million newly diagnosed cancer cases and 12 million deaths, shocking to contemplate in dollars and human suffering. Although this impending disaster has...
Selected Abstracts From 2015 ASH Annual Meeting: Part 3
Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma, and amyloid light-chain (AL) amyloidosis. For other selected abstracts...
Conquer Cancer Foundation Awards Grants to Drive International Cancer Care Advances
The Conquer Cancer Foundation of ASCO has awarded four 2016 International Innovation Grants to organizations developing projects with the potential to revolutionize cancer control in low- and middle-income countries. This year’s grants will support research in India, Nepal, Uganda, and the...
Candid Discussions on Living With and After Cancer at An Evening for Cancer Survivors and Caregivers
On January 14, 2016, the Cancer Survivorship Symposium opened with An Evening for Cancer Survivors and Caregivers, an event featuring networking, a panel discussion, and an open forum to share the challenges of living with or after a cancer diagnosis. The audience included Symposium attendees as...
$13.4 Million Awarded to Study Treatment for Low-Grade Ductal Carcinoma in Situ in a Prospective, Randomized Trial
A funding award of $13.4 million hopes to answer one of the biggest questions in the current management of breast cancer: Do women with the earliest form of the disease, ductal carcinoma in situ (DCIS), need invasive surgery? Researchers at The University of Texas MD Anderson Cancer Center, Duke...
Active Holistic Surveillance May Prevent Unnecessary Biopsies in Low- and Low/Intermediate-Risk Prostate Cancer
The use of prostate-specific antigen (PSA) screening has led to a dramatic rise in the number of men diagnosed with low-grade prostate cancer. Active surveillance is recommended to manage patients with favorable-risk, low-grade prostate cancer, with the goal of avoiding overtreatment of these...
New Technology to Characterize Circulating Tumor Cells Suggests Better Treatment Decision-Making in Prostate Cancer
An early study showed that an experimental blood test (ie, “liquid biopsy”) that characterizes the phenotype and genomic characteristics of circulating tumor cells appears to have utility in personalizing treatment decisions for individual men with advanced prostate cancer.1 The assay—developed and ...
Detection of Thyroid Cancer Most Cost-Effective With Physical Examination, Not Ultrasound Screening
A study evaluating annual physical examination as a screening method to detect thyroid cancer in cancer survivors exposed to neck radiation has shown a substantial cost reduction compared with ultrasound screening, with no thyroid cancer–related mortality.1 According to the analysis, this method...
Expert Point of View: Daniel V.T. Catenacci, MD
In his discussion of the presentation, Daniel V.T. Catenacci, MD, Assistant Professor of Medicine at the University of Chicago, said that conclusions cannot be drawn from the results of NEOSCOPE, which is underpowered to show differences. “On the surface, we see an improvement in the CarPacRT...
Carboplatin/Paclitaxel Tops Oxaliplatin/Capecitabine as Neoadjuvant Regimen for Esophageal Cancer
The United Kingdom’s phase II NEOSCOPE trial compared the toxicity and efficacy of two preoperative chemoradiation regimens—carboplatin/paclitaxel and oxaliplatin/capecitabine—and judged one to be the winner. “CarPacRT passed the prespecified efficacy criteria for taking forward to phase III, but...
Surveillance for Recurrence and Second Cancers: Guidelines and Caveats
Striking the right balance between under- and oversurveillance of cancer survivors is challenging, and oncology providers are best served by knowing and following guidelines—though they can change often. Cancer recurrence and second cancers are two of the major threats to the health of cancer...
Antithymocyte Globulin Reduces Need for Immunosuppressants After Hematopoietic Cell Transplantation From Unrelated Donors
In a phase III trial reported in The Lancet Oncology, Walker et al found that treatment with antithymocyte globulin reduced the need for immunosuppressive therapy in patients with hematologic malignancies receiving hematopoietic cell transplantation from unrelated donors. Study Details In this...
Autoantibodies May Help Detect Lung Cancer Earlier
Preliminary research has identified autoantibodies—immune proteins found in the blood specific for one's own proteins—that can potentially detect lung cancer early by distinguishing between smokers with or without lung cancer and can also discriminate between lung cancer and low-dose...
Anti–PD-1/PD-L1 Antibodies Make Strong Showing in Gastrointestinal Cancers
Although the results may not yet be as impressive as those seen in melanoma, lung, and kidney cancers, monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) are producing responses, with some durability, in gastrointestinal cancers, according to studies presented at the 2016...
Norwegian Male Cancer Survivors Less Likely to Reproduce
A study of all Norwegian men born between 1965 and 1985 showed that male cancer survivors are less likely to have children than those without a cancer diagnosis. “These findings are important for male cancer survivors, seeing as we can identify groups at risk of having reproduction...
ACS/ASCO Breast Cancer Survivorship Care Guideline
The American Cancer Society (ACS) and ASCO have issued a Breast Cancer Survivorship Care guideline, published jointly in the Journal of Clinical Oncology and CA: A Cancer Journal for Clinicians. The guideline recommendations were formulated by a multidisciplinary expert work group and are based on...
Nanoparticle Therapy That Uses LDL and Fish Oil Kills Liver Cancer Cells
An experimental nanoparticle therapy that combines low-density lipoproteins (LDL) and fish oil preferentially kills primary liver cancer cells without harming healthy cells, UT Southwestern Medical Center researchers report. The study was published by Wen et al in Gastroenterology. “This...
Preclinical Device Hits Pancreatic Tumors With Drug Cocktail, Sparing the Body
A highly lethal cancer sometimes requires large doses of highly toxic drugs. However, a blitzkrieg approach can be unfeasible for some patients due to severe side effects. Now a team of researchers at the University of North Carolina at Chapel Hill has found that an implantable device can deliver a ...
Possible Marker for Recurring HPV-Linked Oropharyngeal Cancers
A retrospective analysis of human papillomavirus (HPV) antibodies in patients treated for oropharyngeal cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, said scientists at The Johns Hopkins...
Similar Low Incidence of Bowel Symptoms With Hypofractionated vs Conventionally Fractionated Radiotherapy in Localized Prostate Cancer
As reported by Wilkins et al in The Lancet Oncology, 2-year patient-reported outcomes in a UK phase III trial (CHHiP) substudy have shown a similar low incidence of bowel problems among patients with intermediate-risk localized prostate cancer receiving hypofractionated vs conventionally...
Misconstrued Review
I’ve been a member of ASCO for longer than I can remember. I read most breast cancer–related articles in The ASCO Post and find them helpful, particularly the reports of as-yet-unpublished papers from meetings. So, it is with great disappointment that, in the November 10, 2015, issue, I read a...
Looking at the Real-World Effects of Genetic Testing
According to the most recent estimates, 55% to 65% of women who inherit the BRCA1 mutation and about 45% of women who inherit the BRCA2 mutation will develop breast cancer by the time they are 70 years old. There is also a substantial increase in the probability of developing ovarian cancers in...
How Cancer and Its Treatments Affect Cognitive Function
Although chemotherapy is often cited as the main culprit for diminishing cognitive function in patients with cancer, ushering the term “chemobrain” into the vernacular, research by Tim A. Ahles, PhD, and his colleagues is showing that multiple factors may contribute to the condition.1 Using breast...
Comparing Recurrence Risk With Anastrozole vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ
Two recently reported phase III trials compared adjuvant anastrozole vs tamoxifen in postmenopausal women with hormone receptor–positive ductal carcinoma in situ. As reported in The Lancet by Margolese et al,1 the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial, performed in...
Dose-Intensified vs Standard Salvage Radiation for Biochemically Recurrent Prostate Cancer After Prostatectomy
Initial results of a European phase III trial (SAKK 09/10), reported in the Journal of Clinical Oncology by Ghadjar et al of the Swiss Group for Clinical Cancer Research, showed little difference in acute toxicity with salvage radiotherapy of 70 vs 64 Gy in patients with biochemical recurrence of...
Dutch Trial Indicates 6-Year Surveillance Interval Is Sufficient for Many Individuals With Familial Colorectal Cancer
In a Dutch trial reported in the Journal of Clinical Oncology, Simone D. Hennink, MD, of Leiden University Medical Center in Leiden, the Netherlands, and colleagues found that a 6-year colonoscopic surveillance interval is sufficient for many individuals with familial colorectal cancer.1 However,...
